Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:4960
Name bone marrow cancer
Definition A hematopoietic cancer that derives_from the blood-forming stem cells of the bone marrow.
Source DiseaseOntology.org
Alt Ids DOID:2356 DOID:2761
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
CBL mutant Quizartinib bone marrow cancer sensitive detail...
JAK2 V617F SGI-1776 bone marrow cancer decreased response detail...
JAK2 V617F AZD1208 bone marrow cancer decreased response detail...
JAK2 V617F Ruxolitinib + SGI-1776 bone marrow cancer sensitive detail...
JAK2 V617F AZD1208 + Ruxolitinib bone marrow cancer sensitive detail...
JAK2 V617F CHZ868 bone marrow cancer sensitive detail...
CSF3R mutant N/A bone marrow cancer not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status USA 0
NCT00513474 Phase I Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant Completed USA 0
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed USA 0
NCT00620633 Phase I ATA520 Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation Completed USA 0
NCT00679536 Phase Ib/II anti-thymocyte globulin + Busulfan + Fludarabine Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Unknown status USA 0
NCT00857389 Phase II Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Completed USA 0
NCT00892190 Phase I Dasatinib Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome Completed USA 0
NCT00908167 Phase I Clofarabine + Cytarabine + Sorafenib Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies Completed USA 0
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Completed USA 1
NCT01338987 Phase II Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation Completed USA 0
NCT01584531 Phase II Rigosertib Sodium Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome Completed USA 0
NCT01593670 Phase II Decitabine Aldesleukin Vorinostat Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes Completed USA 0
NCT01606579 Phase Ib/II Cytarabine + PRI-724 Dasatinib + PRI-724 PRI-724 Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies Completed USA 0
NCT01621477 Phase II Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant Terminated USA 0
NCT01634217 Phase I Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation Completed USA 0
NCT01640301 Phase Ib/II Aldesleukin WT1 sensitized T cells Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant Active, not recruiting USA 0
NCT01687400 Phase II Decitabine Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed USA 0
NCT01720225 Phase II Decitabine Azacitidine Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk Completed USA 0
NCT01746849 Phase II Leuprolide Cyclophosphamide Thiotepa Palifermin Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting USA 0
NCT01812252 Phase II Cytarabine + Idarubicin Azacitidine + Decitabine Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant Recruiting USA 0
NCT01823198 Phase Ib/II Methotrexate anti-thymocyte globulin + Busulfan + Fludarabine Tacrolimus Filgrastim Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies Active, not recruiting USA 0
NCT01834248 Phase I Decitabine + Rasdegafusp alfa DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed USA 0
NCT01841333 Phase II Glasdegib PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant Completed USA 0
NCT01842646 Phase II Glasdegib Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) Completed USA 0
NCT01869114 Phase II Azacitidine + Sirolimus Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Active, not recruiting USA 0
NCT01880437 Phase II Cytarabine + Vismodegib A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome Terminated USA | CAN 1
NCT01885689 Phase II Clofarabine + Melphalan Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission Active, not recruiting USA 0
NCT01893320 Phase Ib/II Decitabine + Vosaroxin Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Completed USA 0
NCT01895842 Phase I Ruxolitinib Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Completed USA 0
NCT01926587 Phase Ib/II Azacitidine + Regorafenib Oral Rigosertib in Combination With Azacitidine Completed USA 1
NCT01928537 Phase III Rigosertib Sodium Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Completed USA 7
NCT01953692 Phase I Pembrolizumab A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) Completed 0
NCT01993641 Phase II Pracinostat Azacitidine Decitabine Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Completed USA 0
NCT02010645 Phase II Decitabine + Eltrombopag Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) Terminated USA 0
NCT02076191 Phase Ib/II Decitabine + Ruxolitinib Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML Completed USA 0
NCT02078609 Phase I LGH447 A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) Completed USA 6
NCT02083250 Phase I anti-thymocyte globulin Vorinostat Busulfan + Clofarabine + Fludarabine Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia Active, not recruiting USA 0
NCT02103478 Phase Ib/II Decitabine and Cedazuridine Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS Completed USA | CAN 0
NCT02121418 Phase I Cytarabine + Decitabine Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm Completed USA 0
NCT02129101 Phase I Azacitidine Sonidegib Azacitidine and Sonidegib in Treating Patients With Myeloid Malignancies Completed USA 0
NCT02131597 Phase II Guadecitabine SGI-110 in Higher Risk Myelodysplastic Syndrome (MDS) Active, not recruiting USA 0
NCT02141477 Phase II Decitabine + Omacetaxine mepesuccinate Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Terminated USA 0
NCT02200380 Phase II Plerixafor CDX-301 A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Terminated USA 0
NCT02212561 Phase Ib/II Selinexor Cytarabine Cytarabine + Dexamethasone + Methotrexate Fludarabine Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT02296242 Phase Ib/II Ulixertinib Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes Completed USA 0
NCT02308761 Phase I TEN-010 A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Completed USA 0
NCT02312102 Phase I Bortezomib + Lenalidomide Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation Active, not recruiting USA 0
NCT02319369 Phase I Milademetan Tosylate Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies Terminated USA 0
NCT02333162 Phase I Mycophenolate mofetil Tacrolimus Fludarabine + Melphalan Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Recruiting USA 0
NCT02381548 Phase I Adavosertib + Belinostat Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia Terminated USA 0
NCT02392572 Phase Ib/II ONC201 ONC201 in Relapsed/Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes (HR-MDS) Active, not recruiting USA 0
NCT02400281 Phase Ib/II Azacitidine Crenolanib Cytarabine + Idarubicin Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients Completed USA 0
NCT02418000 Phase Ib/II E6201 A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation Terminated USA 0
NCT02464657 Phase Ib/II Dexamethasone Cytarabine + Idarubicin + Nivolumab Nivolumab in Acute Myeloid Leukemia (AML) Completed USA 0
NCT02469415 Phase II Decitabine Azacitidine Pacritinib Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Terminated USA 0
NCT02472145 Phase III Decitabine Decitabine + Talacotuzumab An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Completed USA 13
NCT02485535 Phase I Selinexor Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Completed USA 0
NCT02527174 Phase I Cytarabine + Idarubicin + Volasertib A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC) Withdrawn CAN 0
NCT02530476 Phase Ib/II Selinexor + Sorafenib Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia Completed USA 0
NCT02577406 Phase III Azacitidine Cytarabine Enasidenib An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY) Active, not recruiting USA | CAN 16
NCT02599649 Phase II Nivolumab Azacitidine Lirilumab Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) Terminated USA 0
NCT02610777 Phase II Azacitidine MLN4924 An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) Completed USA | CAN 10
NCT02721875 Phase I Azacitidine Volasertib Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes Terminated 1
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting USA 0
NCT02728050 Phase Ib/II Sorafenib Cladribine + Cytarabine + Filgrastim + Mitoxantrone Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting USA 0
NCT03065400 Phase II Pembrolizumab PD-1 Inhibition in Advanced Myeloproliferative Neoplasms Completed USA 0